| Expression pattern: |
DS |
| Associated gene: |
IGF2BP2, IGF2BP1, STAT3, TP53, GRWD1 |
| Associated microRNA: |
- |
| Biological function: |
Regulates gene expression programs and proliferative/cell-cycle related pathways in bladder cancer cells by modulating IGF2BP2 availability; affects STAT3 and p53 levels; induces IGF2BP2 condensates upon overexpression. |
| Molecular mechanism: |
circHIPK3 binds the RBP IGF2BP2 via an 11-mer motif and functions as a ceRNA/competitive binder, altering IGF2BP2 binding to target mRNAs (e.g., STAT3) and likely promoting IGF2BP2 condensation (phase separation) to modulate mRNA stability. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); cell cycle (inhibits); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RT-qPCR; RNA-seq; RNase R Treatment; Northern Blot; RIP (RNA Immunoprecipitation); Transfection; Western Blot; IF (Immunofluorescence); Cell Cycle Assay; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circHIPK3 expression is positively associated with overall survival in bladder cancer patients; circHIPK3 is higher in NMIBC than in MIBC. |
| Description: |
In bladder cancer models, circHIPK3 binds IGF2BP2 through an 11-mer motif and modulates IGF2BP2 engagement with target mRNAs (e.g., STAT3), consistent with an RBP-focused ceRNA-like mechanism affecting mRNA stability. circHIPK3 overexpression promotes formation of IGF2BP2 condensates, suggesting a nucleation/phase-separation component. Clinically, higher circHIPK3 levels are associated with better overall survival in NMIBC cohorts. |
| Confidence score: |
0.8397 |